{"id":1018882,"date":"2026-11-09T10:37:24","date_gmt":"2026-11-09T15:37:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"},"modified":"2026-11-09T10:37:24","modified_gmt":"2026-11-09T15:37:24","slug":"cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","title":{"rendered":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Nov.  09, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1OucnqOFJWlboJqVcH6oOtoAQc3h_O1r3ADwcNtt7l6IJDy64bqK0Tm9Q-joBh0fKy6FPd49E0MFoI6METheCarymCeBAguJIQLzJ_U568CpGxwn9bXTsn5v2qcd4UyWehj1RjHICr0h8C61ramxIiir6aB19jXRxp3R3ZdT0OCle5HHAtvYyZ8ZYse90nEQ9ymlpsM1ZTlP4e24fIcweYtTlEL5XG59DkJN7UTWEBP-ibxZr7sq_irHSRX-7GbobaqowyOH9uxuOBGZ658BriAZ8O9l-rj18dKK2adNsnpfxHr-WLPy-84dtUUDnG0I\" rel=\"nofollow\" target=\"_blank\"><strong>Cullinan Therapeutics, Inc.<\/strong><\/a> (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 2:40 p.m. ET.<\/li>\n<li style=\"margin-bottom:8pt\">Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the UBS Global Biopharma Conference 2026 in London, UK on Tuesday, November 17, 2026, at 2:00 p.m. GMT (9:00 a.m. ET).<\/li>\n<\/ul>\n<p>Webcasts of the fireside chats will be available under the Events and Presentations section of the Company\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IvrCOY_is9l2Ypp_tFu0tABiRVHghxvgZW3rA1hT50NG1qvo3BZOhY3on8l51KiLmn4aMshwBeC-UgN_gIkBbNHi3lkJ0boueoYFge6Z1LjDzI76TXrZCQzwtY2D0hOORy7EERGWHxeQZ14gcMEwnR5Fha_7U6AUvOp-0D9raV9iR7Hrh0XmgJNPlYc2iJX_1f3feFQ8dOtw5EO-oGz83fZ4Xze3bHLtKYiH3Of4vmPFxdlnJ7h_NA64NfQUfvS9MlQP47YS4_9GBtFSYTtf4EgCUkuiI_q5dH12NmylIggyozZW2ecRXBRyPmA3g7wU_4FFCpROoyWLQ4tW66pZnGK7hTQTQMEeRL0Ekmt_IXHssyRGcr6WncQGb0xmmtfX25TBI_r1mNuoZofkWxSemA==\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/investors.cullinantherapeutics.com\/events<\/strong><\/a>.<\/p>\n<p>\n        <strong>About Cullinan Therapeutics<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1OucnqOFJWlboJqVcH6oOtoAQc3h_O1r3ADwcNtt7l5nFDLneCo28LAScd_pwH3ejUWJ1pE5_FYfvvT8KwIi0xBN_s-xJBNUTVm8ZkwJJgOLCLyMHtY9H0bk20ROziP2HxD57F5TXVPzUyeTOvlmRxxfbtYpDRTGM_8GmQSnWLNk0ZXhrjVIx_AuHM0eG_9ajgxgSm7nOvxvrWQ5eEjlCbFJDw3LjFLcuZ1zdvlT4m7BnO96btQyleORKf2vE3b727Jv1PBQwcw2iWZCuu3NzOfgeQ1lE6t2eK_4IgnzsTcTVp664aElxp40et4u7ZE9\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Cullinan Therapeutics, Inc.<\/strong><br \/>\n        <\/a>\u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IvrCOY_is9l2Ypp_tFu0tO3oxf8tl06odS0IkaK1isDMd2YvZntACoyKSImwroO_HCbxJJ_DcVmD5fmY0n8AM8ssJqdWzLhPLOpyfOp8axJ4zbnqDp59s50M-hceHbqGYP8T8AROOFVCEQc_-gbNO5Nlk9Bo8gCmg1PvbCg1BQlZtfwgzqoxFB_fptQUtOYAW-GavNlpvwrP-unk0Synen7lkNsPWy_N1ZGzqLt-9Y68Z5JqxV8NtzdIkWfiIcV63_-qCOm8UdygbLIrEX9OvqSa8X_NnrX8r_kZsYp_kalO_Iu1E6ichhPDSI7tOfLd\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/cullinantherapeutics.com\/<\/strong><\/a>, and follow Cullinan on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-MsPKzOAorbyr1raiUkkzHZFBrzjurWxYhUY_Paewo9qCwilBOPsN5Uhx5mNJFQfol42qOTtxgNg8Ab8ewSZVSR9JoZB6QELasNTrx35XuJyRhHDWRMM5tN5b536wpQU55vbD0muJ9JLdzkRuIoRmk6cfem7LTUmYAe4pL5Kt0sS3pDiCgSvbASHx6gZgknU2S-2FoGp_pezYt0fkek4vfJ6z0HwqB-4sYmmKlqLzjRKqT3TqXy7xLdFdno71KbC\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SlZi-Bz3Pg4HFBLqOJwjloghCEuDkYZ9V8KrooosczP-NEPVml3I9WShN5xzcQ-VAd6aWyjbtPaC5QcS88CbTGY1d-iJAiYFfMeKk6fT-rmAL_go_7fdY-oDwcz6w2qauWIX4caPJsGto9pDVvPpOPetRA7R-BNQqabnimK3LXZsAFSKEKlcx0qftJwvc9Qbt4d6Eygo1WeQIi7wGed5Lg==\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Nick Smith<br \/>+1 401.241.3516<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=04SU21z9qgdBmUw37uwhwJi5EBDnWscn9wCmCGCd3gc115qm_Jby8uF7eRPq4yafWW-L2IPcnQNucLUlyWMDeiVaqaiir5y1pFBaL6kAXT_dRpMGZ3FN1VPuKg76x0gzbqkYoBD_N2ZR3BrgVvxHGGtMqWrWXTDlVTfBMFKtlds2AX4j8ay1Q_n7avyTUtBBG_s8wJsylUfuPDnN8FIF-UrYPZqMWkRkYFLJg_HqV6TSCmlHzQI0Kg91FIsrYg1u8V20AxD8b2KkiA0EnLr2fg==\" rel=\"nofollow\" target=\"_blank\">Nsmith@cullinantx.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Rose Weldon<br \/>+1 215.801.7644<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BCPmEMq06Rhq6rv3DWg7Hthy0yuGPDapHsocr4KZvqF_yQpIDW5v-oVnxGm1BPmJ85p3GKgGstaHhCG7VsXf68LlqZDwq5iTPpVrtM8F9uZtgiNn2fjrV60GM4OKYJ0V90SSvyl4u2imOMLHQ8UIFRlFNxLL4Rsv-gsWV1KFKXQWl1l1t394V492vlIBbE5Az6x_smbqB9NDHjlzuQdj02J-s_roGtk_aUWYVf_ouSA5tkAr12xcvygh4A8nS50oIMrLdHmF3ma9TE2_i50ReQ==\" rel=\"nofollow\" target=\"_blank\">Rweldon@cullinantx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2QxOGU4YzQtMDdiMi00MmNhLWE4ZGQtMDBiYTg4ZmNkZTEyLTEyMTc0MjYtMjAyNi0xMS0wOS1lbg==\/tiny\/Cullinan-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 2:40 p.m. ET. Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the UBS Global Biopharma Conference 2026 in London, UK on Tuesday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cullinan Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018882","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 2:40 p.m. ET. Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the UBS Global Biopharma Conference 2026 in London, UK on Tuesday, &hellip; Continue reading &quot;Cullinan Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T15:37:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cullinan Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-11-09T15:37:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\",\"name\":\"Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\",\"datePublished\":\"2026-11-09T15:37:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cullinan Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM; \u201cCullinan\u201d), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 2:40 p.m. ET. Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the UBS Global Biopharma Conference 2026 in London, UK on Tuesday, &hellip; Continue reading \"Cullinan Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T15:37:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-11-09T15:37:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/","name":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=","datePublished":"2026-11-09T15:37:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MzMxNiM3OTU0MDc2IzIyMDU4NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-participate-in-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cullinan Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018882"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}